°øÁö»çÇ×

HOME > ÇÐȸ¼Ò°³   >   °øÁö»çÇ×

[11¿ù 19ÀÏ]Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö ¾È³»
ÀÛ¼ºÀÚ
°ü¸®ÀÚ
ÀÛ¼ºÀÏ
2016-11-17
Á¶È¸
3047

 

 

Á¦ 6ȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¿ò (¾È)

Àå¼Ò : ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ 132È£ °­ÀǽÇ

 

1:00~1:10 °³È¸»ç (¿ï»êÀÇ´ë ¹Ú»ó±Ô)

Session I. Individualized management for hemophilia patients (ÁÂÀå °æÈñÀÇ´ë À±ÈÖÁß)

1:10~1:40 Personalized treatment and prophylaxis for hemophilia A and B (ÃæºÏÀÇ´ë ¹Ú¹Ì¸²)

1:40~2:10 Current strategies for reducing inhibitor developments and fighting against inhibitors (°æÈñÀÇ´ë ¹Ú¿µ½Ç)

2:10~2:40 The basis of population Pharmacokinetics in hemophilia patients (¿¬¼¼ÀÇ´ë ¾à¸®Çб³½Ç ¼Õ¹ÌÁ¤)

2:40~3:00 Coffee break

Session II Update for current research and treatment trends for hemophilia (ÁÂÀå ÀÎÇÏÀÇ´ë ±è¼ø±â)

3:00~3:20 Current trends in von Willebrand Disease (¿ï»êÀÇ´ë ¹Ú»ó±Ô)

3:20~3:40 Update for novel therapeutics in hemophilia (¿¬¼¼ÀÇ´ë ÇÑÁ¤¿ì)

3:40~4:00 Multidisciplinary management of hemophilia (´ë±¸°¡Å縯ÀÇ´ë ÃÖÀºÁø)

4:00~4:30 Trends and suggestion on the national hemophilia registry (Ç÷¿ìÀç´Ü À¯±â¿µ)

4:30~4:50 Discussion

4:50~5:00 Æóȸ ¹× »çÁøÃÔ¿µ